DK0980252T3 - Terapier til akut nyresvigt - Google Patents

Terapier til akut nyresvigt

Info

Publication number
DK0980252T3
DK0980252T3 DK98919715T DK98919715T DK0980252T3 DK 0980252 T3 DK0980252 T3 DK 0980252T3 DK 98919715 T DK98919715 T DK 98919715T DK 98919715 T DK98919715 T DK 98919715T DK 0980252 T3 DK0980252 T3 DK 0980252T3
Authority
DK
Denmark
Prior art keywords
renal failure
acute renal
therapies
risk
treatment
Prior art date
Application number
DK98919715T
Other languages
Danish (da)
English (en)
Inventor
Kuber T Sampath
Charles M Cohen
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of DK0980252T3 publication Critical patent/DK0980252T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK98919715T 1997-05-05 1998-05-05 Terapier til akut nyresvigt DK0980252T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4561997P 1997-05-05 1997-05-05
PCT/US1998/003197 WO1998050060A1 (en) 1997-05-05 1998-05-05 Therapies for acute renal failure
EP98919715A EP0980252B1 (en) 1997-05-05 1998-05-05 Therapies for acute renal failure

Publications (1)

Publication Number Publication Date
DK0980252T3 true DK0980252T3 (da) 2005-01-31

Family

ID=21938961

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98919715T DK0980252T3 (da) 1997-05-05 1998-05-05 Terapier til akut nyresvigt

Country Status (11)

Country Link
US (2) US20100105621A1 (ja)
EP (1) EP0980252B1 (ja)
JP (2) JP5033276B2 (ja)
AT (1) ATE278414T1 (ja)
AU (1) AU743510B2 (ja)
CA (1) CA2289123A1 (ja)
DE (1) DE69826854T2 (ja)
DK (1) DK0980252T3 (ja)
ES (1) ES2226125T3 (ja)
PT (1) PT980252E (ja)
WO (1) WO1998050060A1 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1255569B1 (en) * 2000-01-31 2010-09-15 Uwe Waldemar Rothenpieler Pax2 for treating kidney disorders
US7612046B2 (en) 2000-01-31 2009-11-03 Uwe Waldemar Rothenpieler Method for treating kidney disorders
CA2452114C (en) 2001-06-26 2010-11-16 Takeda Chemical Industries, Ltd. Tgf-.beta. superfamily production/secretion promoter
EP1578360A4 (en) * 2002-08-28 2009-10-21 Curis Inc JOINT ADMINISTRATION OF MORPHOGENES AND ANGIOTENSIN ENZYME CONVERTING INHIBITORS FOR THE TREATMENT OF CHRONIC RENAL FAILURE
WO2007056614A1 (en) * 2005-11-14 2007-05-18 Merial Limited Gene therapy for renal failure
US8025881B2 (en) 2006-07-21 2011-09-27 Chugai Seiyaku Kabushiki Kaisha BMP antibodies and methods of treating kidney disease using the same
US8979797B2 (en) * 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
IL247111B1 (en) 2014-02-07 2024-03-01 Toru Miyazaki causes the prevention of or treatment of kidney disease
FR3071065B1 (fr) 2017-09-08 2020-10-02 Dcns Dispositif de controle d'isolement et/ou de continuite d'au moins un cable electrique et procede de controle associe

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4627839A (en) * 1985-11-21 1986-12-09 American Hospital Supply Corporation Patient controlled analgesia conversion
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5266683A (en) * 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5045452A (en) * 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
DK0429570T3 (da) 1989-03-28 1998-04-27 Genetics Inst Osteoinducerende præparater
EP0536186B1 (en) 1990-05-16 2001-11-21 Genetics Institute, Inc. Bone and cartilage inductive proteins
JPH0426624A (ja) 1990-05-18 1992-01-29 Tsumura & Co 慢性腎不全改善剤
ATE146076T1 (de) 1990-06-22 1996-12-15 Du Pont Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten
CA2363965C (en) * 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US7056882B2 (en) * 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US6194376B1 (en) * 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
DK0575555T3 (da) 1991-03-11 2001-11-05 Curis Inc Proteininduceret morfogenese
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
CA2116560C (en) 1991-08-30 2002-01-08 Charles M. Cohen Morphogenic protein screening method
EP0601135B1 (en) * 1991-08-30 2005-11-02 Curis, Inc. Osteogenic proteins in the treatment of metabolic bone diseases
WO1993004692A1 (en) * 1991-08-30 1993-03-18 Creative Biomolecules, Inc. Morphogen-induced modulation of inflammatory response
US6120760A (en) * 1992-02-12 2000-09-19 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Growth/differentiation factors of the TGF-β family
KR950702627A (ko) 1992-07-31 1995-07-29 찰스 엠. 코헨 모르포겐 단백질의 가용성 복합체 및 그의 조성물(Morphogenic Protein Soluble Complex and Composition Thereof)
DK0653942T3 (da) * 1992-07-31 2003-10-20 Curis Inc Morphogen-induceret nerve-regenerering og -reparation
EP0661933B1 (en) 1992-07-31 1998-04-22 Creative Biomolecules, Inc. Morphogen-enriched dietary composition
JP3973050B2 (ja) 1992-09-16 2007-09-05 キュリス，インコーポレイテッド モルフォゲン誘発性肝再生
EP0672064A1 (en) 1992-11-03 1995-09-20 Creative Biomolecules, Inc. Op-3-induced morphogenesis
WO1994020539A1 (en) 1993-03-04 1994-09-15 Creative Biomolecules, Inc. Method and compositions for recombinant osteogenic protein production
US5631159A (en) 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
CA2176709A1 (en) * 1993-11-15 1995-05-26 Howard R. Higley Method of treating renal disease by administering igf-i and igfbp-3
US5525621A (en) * 1994-05-20 1996-06-11 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
ATE493141T1 (de) * 1996-03-22 2011-01-15 Stryker Corp Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
US5820589A (en) * 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5879908A (en) * 1997-04-30 1999-03-09 Smithkline Beecham Corporation CRFG-1a, a target and marker for chronic renal failure
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity

Also Published As

Publication number Publication date
DE69826854D1 (de) 2004-11-11
JP2009286802A (ja) 2009-12-10
EP0980252B1 (en) 2004-10-06
ATE278414T1 (de) 2004-10-15
DE69826854T2 (de) 2006-02-02
PT980252E (pt) 2005-01-31
CA2289123A1 (en) 1998-11-12
US20100105621A1 (en) 2010-04-29
AU7244398A (en) 1998-11-27
ES2226125T3 (es) 2005-03-16
JP2001523264A (ja) 2001-11-20
JP5033276B2 (ja) 2012-09-26
EP0980252A1 (en) 2000-02-23
WO1998050060A1 (en) 1998-11-12
US20110257093A1 (en) 2011-10-20
AU743510B2 (en) 2002-01-24
US8748378B2 (en) 2014-06-10

Similar Documents

Publication Publication Date Title
ATE277629T1 (de) Morphogenische behandlung des chronischen nierenversagens
DK0980252T3 (da) Terapier til akut nyresvigt
EA199801044A1 (ru) Модуляторы регенерации тканей
DK1238658T3 (da) Understöttet afgivelse af et aktivt middel under anvendelse af et implanterbart system
ATE256463T1 (de) Pharmazeutische zubereitung zur verwendung in der behandlung von diabetes
SE8501050D0 (sv) Biologically active fragments of human antihemophilic factor and method for preparation thereof
FI962154A0 (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
ATE273031T1 (de) Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
MX9801596A (es) Composiciones aliviadoras del prurito, cosmeticas y farmaceuticas o ambas.
Dawson et al. The periosteal requirement and temporal dynamics of BMP2‐induced middle phalanx regeneration in the adult mouse
NO865068D0 (no) System, fremgangsmaate og apparat til fraksjonering av blod in situ.
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DE69228997T2 (de) Menschliche il-3-varianten
NO972849D0 (no) Peptid p277 analoger og farmasöytiske sammensetninger som omfatter disse for behandling eller diagnostikk av diabetes
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
BR9709900A (pt) Proteìnas de ligacão de proteìnas de prìons e usos das mesmas.
TR199900596T2 (xx) Otoim�n hastal�klara kar�� maddeler olarak proteinlerin kullan�m�.
DE69721484D1 (de) Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten
DK0653939T3 (da) Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner
ATE363072T1 (de) Monoklonaler antikörper gegen mxa und mxb
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
FR2764389B1 (fr) Utilisation de venin de crotalus viridis helleri, procede et necessaire pour la determination de la reactivite de la proteine c activee
DK1214091T3 (da) Terapier til kronisk nyresvigt under anvendelse af én eller flere integrinantagonister
ATE232738T1 (de) Kolostrum enthaltende pharmazeutische zusammensetzungen und deren verwendung